Future drugs for migraine

Internal and Emergency Medicine

Volumn 4, Issue 5, 2009, Pages 367-373

  Farinelli, Ivano ^a   de Filippis, Sergio ^a   Coloprisco, Gabriella ^a   Missori, Serena ^a   Martelletti, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute treatment; CGRP antagonists; Glutamate receptor antagonists; Migraine; Neurotoxins; Preventative therapy

Indexed keywords

AMINO ACID RECEPTOR BLOCKING AGENT; CALCITONIN GENE RELATED PEPTIDE; VASODILATOR AGENT;

DRUG EFFECT; FEMALE; HUMAN; MALE; MIGRAINE; NERVOUS SYSTEM; REVIEW;

CALCITONIN GENE-RELATED PEPTIDE; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; NERVOUS SYSTEM; VASODILATOR AGENTS;

EID: 71449123323     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-009-0273-0     Document Type: Review

References (55)

1. Stovner LJ, Andrée C, on behalf of the Eurolight Steering Committee (2008) Impact of headache in Europe: a review for the Eurolight project. J Headache Pain 9: 139-146.
2. Piane M, Lulli P, Farinelli I et al (2007) Genetics on migraine and pharmacogenomics: some considerations. J Headache Pain 8: 334-339.
3. Di Piero V, Altieri M, Conserva G, Petolicchio B, Di Clemente L, Hietarachchi J (2007) "General practitioners' co-operative" of the Casilino District of Rome. J Headache Pain 8: 205-208.
4. Steiner TJ, Paemeleire K, Jensen R et al (2007) European principles of management of common headache disorders in primary care. J Headache Pain 8: S3-S47.
5. Tfelt-hansen P (2007) Acute pharmacotherapy of migraine, tension-type headache, and cluster headache. J Headache Pain 8: 127-134.
6. Martelletti P, Farinelli I, Colorisco G, Patacchioli FR (2007) Role of NSAIDs in acute treatment of headache. Drug Develop Res 68: 276-281.
7. Ferraro D, Di Trapani G (2008) Topiramate in the prevention of paediatric migraine: literature review. J Headache Pain 9: 147-150.
8. Valade D (2008) The emergency headache Center at the Lariboisière Hospital: 7 years with more than 70, 000 patients. Intern Emerg Med 3: S3-S7.
9. Martellett P, Farinelli I, Steiner TJ, Working Group for Specialist Education, WHO's Global Campaign to Reduce the Burden of Headache Worldwide (Lifting The Burden) (2008) Acute migraine in the emergency department: extending European principles of management. Intern Emerg Med 3: S17-S24.
10. Link AS, Kuris A, Edvinsson L (2008) Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system. J Headache Pain 9: 5-12.
11. Lassen LH, Jacobsen VB, Haderslev PA et al (2008) Involvement of calcitonin gene-related peptide in migraine: regional blood flow and blood flow velocity in migraine patients. J Headache Pain 9: 151-157.
12. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J (2002) CGRP may play a causative role in migraine. Cephalalgia 22: 54-61.
13. Gupta R, Ahmed T, Banerjee B, Bhatia M (2009) Plasma calcitonin gene-related peptide concentration is comparable to control group among migraineurs and tension-type headache subjects during inter-ictal period. J Headache Pain. doi: 10. 1007/s10194-009-0110-x.
14. Edvinsson L, Alm R, Shaw D et al (2002) Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells. Eur J Pharmacol 434: 49-53.
15. Olesen J, Diener HC, Husstedt IW et al (2004) Calcitonin gene-related peptide receptor antagonist BIBN4096BS for the acute treatment of migraine. N Engl J Med 350: 1104-1110.
16. Salvatore CA, Hershey JC, Corcoran HA et al (2008) Pharmacological characterization of MK-0974 [N-[(3R, 6S)-6-(2, 3-difluorophenyl)-2-oxo-1-(2, 2, 2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2, 3-dihydro-1H-imidazo[4, 5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther 324: 416-421.
17. Ho TW, Mannix LK, Fan X et al (2008) Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70: 1304-1312.
18. Ho TW, Ferrari MD, Dodick DW et al (2008) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372: 2115-2123.
19. Markowitz S, Saito K, Moskowitz MA (1987) Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J Neurosci 7: 3129-3136.
20. Murata Y, Masuko S (2006) Peripheral and central distribution of TRPV1, substance P and CGRP of rat corneal neurons. Brain Res 1085: 87-94.
21. Storer RJ, Akerman S, Goadsby PJ (2004) Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 142: 1171-1181.
22. Szallasi A, Cruz F, Geppetti P (2006) TRPV1: a therapeutic target for novel analgesic drugs? Trends Mol Med 12: 545-554.
23. Chizh BA, O'Donnell MB, Napolitano A et al (2007) The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain 132: 132-141.
24. Nicoletti P, Trevisani M, Manconi M et al (2008) Ethanol causes neurogenic vasodilation by TRPV1 activation and CGRP release in the trigeminovascular system of the guinea pig. Cephalalgia 28: 9-17.
25. Farinelli I, Martelletti P (2007) Aspirin and tension-type headache. J Headache Pain 8: 49-55.
26. Nakao K, Murase A, Ohshiro H et al (2007) CJ-023423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 322: 686-694.
27. Maubach KA, Davis RJ, Clark DE et al (2009) G BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol 156: 316-327.
28. Castro ME, Pascual J, Romón T, del Arco C, del Olmo E, Pazos A (1997) Differential distribution of [3H]sumatriptan binding sites (5-HT1B, 5-HT1D and 5-HT1F receptors) in human brain: focus on brainstem and spinal cord. Neuropharmacology 36: 535-542.
29. Panconesi A (2008) Serotonin and migraine: a reconsideration of the central theory. J Headache Pain 9: 267-276.
30. Ayzenberg I, Oberman M, Leineweber K et al (2008) Increased activity of serotonin uptake in platelets in medication overuse headache following regular intake of analgesics and triptans. J Headache Pain 9: 109-112.
31. Goldstein DJ, Roon KI, Offen WW et al (2001) Selective serotonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet 358: 1230-1234.
32. Olesen J (2008) The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. Pharmacol Ther 120: 157-171.
33. Christiansen I, Iversen HK, Olesen J, Tfelt-hansen P (2008) Nitric oxide-induced headache may arise from extracerebral arteries as judged from tolerance to isosorbide-5-mononitrate. J Headache Pain 9: 215-220.
34. Lassen LH, Ashina M, Christiansen I, Ulrich V, Olesen J (1997) Nitric oxide synthase inhibition in migraine. Lancet 349: 401-402.
35. Alderton WK, Angell AD, Craig C et al (2005) GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. Br J Pharmacol 145: 301-312.
36. Simpson LL (1980) Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 213: 504-508.
37. Eleopra R, Tugnoli V, Rossetto O, De Grandis D, Montecucco C (1998) Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 256: 135-138.
38. Durham PL, Cady R, Cady R (2004) Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44: 35-43.
39. Dodick DW, Mauskop A, Elkind AH et al (2005) Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 45: 315-324.
40. Saper JR, Mathew NT, Loder EW, BoNTA-009 Study Group et al (2007) A double-blind, randomized, placebo-controlled comparison of botulinum toxin type A injection sites and doses in the prevention of episodic migraine. Pain Med 8: 478-485.
41. Evers S (2007) Review of botulinum toxin type A for the prophylactic treatment of chronic daily headache. Neuropsychiatr Dis Treat 3: 761-764.
42. Cady R, Schreiber C (2008) Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Headache 48: 900-913.
43. Relja M, Poole AC, Schoenen J et al (2007) A multi-centre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 27: 492-503.
44. Ma QP (2001) Co-localization of 5-HT(1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats. Neuroreport 12: 1589-1591.
45. Peres MF, Zukerman E, Senne Soares CA, Alonso EO, Santos BF, Faulhaber MH (2004) Cerebrospinal fluid glutamate levels in chronic migraine. Cephalalgia 24: 735-739.
46. Sang CN, Ramadan NM, Wallihan RG et al (2004) LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well tolerated in acute migraine. Cephalalgia 24: 596-602.
47. Weiss B, Alt A, Ogden AM et al (2006) Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo. J Pharmacol Exp Ther 318: 772-781.
48. Damodaram S, Thalakoti S, Freeman SE, Garrett FG, Durham PL (2009) Tonabersat inhibits trigeminal ganglion neuronal-satellite glial cell signaling. Headache 49: 5-20.
49. MaassenVanDenBrink A, van den Broek RW, de Vries R, Upton N, Parsons AA, Saxena PR (2000) The potential anti-migraine compound SB-220453 does not contract human isolated blood vessels or myocardium; a comparison with sumatriptan. Cephalalgia 20: 538-545.
50. Tvedskov JF, Iversen HK, Olesen J (2004) A double-blind study of SB-220453 (tonerbasat) in the glyceryltrinitrate (GTN) model of migraine. Cephalalgia 24: 875-882.
51. Goadsby PJ, Ferrari MD, Csanyi A, Olesen J, Mills JG (2009) Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Cephalalgia. doi: 10.1111/j.1468-2982.2008.01804.x.
52. Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G (2003) Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 289: 65-69.
53. Diener HC, Sacco RL, Yusuf S et al (2008) Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the prevention regimen for effectively avoiding second strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol 7: 875-884.
54. Allena M, Katsarava Z, Nappi G, The COMOESTAS Consortium (2009) From drug-induced headache to medication overuse headache: a short epidemiological review, with a focus on Latin-American countries. J Headache Pain 10: 71-76.
55. Ferrari A, Spaccapelo L, Gallesi D, Sternieri E (2009) Focus on headache as an adverse reaction to drugs. J Headache Pain. doi: 10. 1007/s10194-009-0127-1.